Wenxin Liu

Dr. Wenxin Liu


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2025 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
JSJindong Sheng
Jindong Sheng
HLHaitao Luo
Haitao Luo
XLXiangyu Liu
Xiangyu Liu
CLChunyan Liu
Chunyan Liu
WZWenhao Zhou
Wenhao Zhou
WLWenxin Liu
Wenxin Liu
The clinical benefit of neoadjuvant immunochemotherapy in locally advanced cervical cancer (LACC) remains unclear. This single-arm, phase II study (Chinese Clinical Trial Registry, ChiCTR2200065392) aimed to evaluate the efficacy and safety of neoadjuvant anti-programmed cell death protein 1 (PD-1) antibody tislelizumab in combination with chemotherapy in treatment-naïve patients with stage IB3/IIA2 LACC. Enrolled patients received tislelizumab (200 mg, every 3 weeks) plus chemotherapy for 3 cycles before radical surgery. The primary endpoint was the pathological complete response (pCR). Secondary endpoints were objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1, disease-free survival, overall survival, and safety. Exploratory endpoints included tissue-based and blood-based biomarkers to identify the biological drivers behind the clinical outcomes. Between November 2022 and March 2024, 30 patients were enrolled. All patients completed 3 cycles of neoadjuvant immunochemotherapy and underwent radical surgery. The pCR was observed in 20 (66.7%) patients, and 4 (13.3%) patients achieved major pathological response (MPR), with an optimal pathological response rate (OPR) of 80.0%. The ORR was 90.0%, with 17 (56.7%) complete responses. Survival data were immature at the median follow-up of 14.7 months (data cutoff, December 31, 2024). Grade 3 treatment-related adverse events (TRAEs) and immune-related AEs occurred in 26.7% and 3.3% of patients, respectively. No treatment-related death occurred. Patients with pCR had significantly higher expression of PD-L1 CPS at baseline, and a strong relationship with immune-related signature (all p < 0.05). Neoadjuvant tislelizumab plus chemotherapy showed promising antitumor efficacy and a well-tolerated safety profile in patients with stage IB3/IIA2 LACC, and might be a potential option in this population.

4 March 2026 in ACS Omega
Verified
Journal Article
Open access
Yuanjie CaoYuanjie Cao
Yuanjie Cao
YZYunying Zhao
Yunying Zhao
JLJing Luan
Jing Luan
Yan LuYan Lu
Yan Lu
WLWenxin Liu
Wenxin Liu
LZLinlin Zhao
Linlin Zhao
Hypoxia severely limits the efficacy of photodynamic therapy (PDT) because oxygen shortage suppresses the generation of cytotoxic reactive oxygen species (ROS). Here we report near-infrared (NIR)-responsive, oxygen self-sufficient nanoparticles (TANPs) that integrate photothermal therapy (PTT) with thermally activated, oxygen self-sufficient PDT and are designed to enhance phototherapy performance in oxygen-deficient settings. TANPs were obtained by nanoprecipitation of an A-D-A type photothermal agent (3TT-IC-4Cl) and a thermally activatable endoperoxide (APO) in DSPE-PEG2000. The nanoparticles showed a uniform spherical morphology with an average hydrodynamic diameter of ∼150 nm, strong NIR absorption, and excellent colloidal and photothermal stability. Upon 880 nm irradiation, TANPs generated robust hyperthermia (ΔT > 50 °C at 180 μg/mL) with a photothermal conversion efficiency of 30.96% and simultaneously produced ROS via thermally triggered APO activation. In vitro, TANPs exhibited negligible dark cytotoxicity but marked light-induced cytotoxicity toward HeLa and 293 cells, outperforming single-mode control nanoparticles (TNPs or ANPs). Flow cytometry confirmed that TANPs induced pronounced early and late apoptosis as a result of combined hyperthermia and ROS-mediated damage. These findings suggest that TANPs constitute a promising nanoplatform to boost phototherapeutic efficacy in oxygen-deficient tumor microenvironments.

23 June 2026 in Journal of Translational Medicine
Verified
Journal Article
Open access
JSJindong Sheng
Jindong Sheng
YXYiwen Xing
Yiwen Xing
JLJing Luan
Jing Luan
XLXiangyu Liu
Xiangyu Liu
HSHualin Song
Hualin Song
KWKe Wang
Ke Wang
Background: Ovarian cancer is a highly lethal gynecologic malignancy, with metabolic reprogramming being a key contributor to its progression and therapeutic resistance. Although Secreted Frizzled-Related Protein 2 (SFRP2) has been implicated in various cancers, its functional role and molecular mechanisms in ovarian cancer, particularly in regulating metabolic pathways, remain poorly defined. Methods: Bioinformatic analyses of GEO (GSE66957) and TCGA-OV datasets were performed to assess SFRP2 expression and its prognostic correlation. Immunohistochemistry (IHC) on a human ovarian cancer tissue microarray was used for clinical validation. SFRP2 was knocked down or overexpressed in ovarian cancer cell lines (HEY and SK-OV-3) using lentiviral shRNA vectors. Functional assays (CCK-8, colony formation, apoptosis, migration) and metabolic assays (glucose consumption, lactate/ATP production, ECAR/OCR) were conducted. The mechanistic link between SFRP2, transcription factor CEBPA, and downstream target PTK2B was investigated using co-immunoprecipitation (Co-IP), nuclear-cytoplasmic fractionation, chromatin immunoprecipitation (ChIP), and dual-luciferase reporter assays. Rescue experiments were performed both in vitro and in vivo (xenograft mouse models). Results: SFRP2 was significantly overexpressed in ovarian cancer tissues and cell lines, and high SFRP2 expression correlated with advanced disease and poor patient survival. SFRP2 knockdown suppressed cell proliferation, colony formation, and migration, while promoting apoptosis. Mechanistically, SFRP2 interacted with the transcription factor CEBPA, promoted its nuclear translocation, and enhanced its occupancy at the PTK2B promoter, thereby driving PTK2B transcriptional activation. This SFRP2/CEBPA/PTK2B axis further activates the AKT/mTOR signaling pathway, upregulating key glycolytic enzymes. Importantly, inhibiting glycolysis with 2-DG or knocking down PTK2B effectively reversed the oncogenic effects of SFRP2 both in vitro and in vivo. Conclusion: Our findings identify a novel SFRP2/CEBPA/PTK2B signaling axis that drives aerobic glycolysis and malignant progression in ovarian cancer, highlighting SFRP2 and PTK2B as potential prognostic markers and therapeutic targets.

4 October 2025 in Cancer Treatment and Research Communications
Verified
Journal Article
Open access
JSJindong Sheng
Jindong Sheng
JLJing Luan
Jing Luan
YZYujie Zhao
Yujie Zhao
YXYiwen Xing
Yiwen Xing
WCWenfeng Cao
Wenfeng Cao
WLWenxin Liu
Wenxin Liu
Synchronous multiple malignant neoplasms (SMMNs) in gynecology involving the ovary, endometrium, and cervix are rare and pose a significant diagnostic challenge when the primary lesion is unclear. We performed targeted genomic sequencing, immunohistochemical analysis and copy number analysis on multiple samples from one patient with simultaneous cancerous lesions in ovary, endometrium and cervix, to clarify tumor clonal origin and divergent evolutionary relationships. Using blood-derived genomic DNA as reference, targeted sequencing of 1012 genes across endometrial, ovarian, and cervical sites identified two germline and 96 somatic mutations. A germline MSH2 splice acceptor site mutation confirmed Lynch syndrome. Tumor across distinct anatomical sites shared three genetic mutations: an MSH2 missense mutation, a FAT1 missense mutation, and an SH3GL1 in-frame deletion. These rare mutations of uncertain clinical significance support a shared clonal origin. Ovarian lesions showed the highest shared somatic mutation frequency, indicating an ovarian origin. Phylogenetic reconstruction revealed branched evolution, indicating metastasis from ovary to endometrium and cervix. Diverse mutation forms in ARID1A, PTEN, ERBB2, and PIK3CA across different lesions suggest convergent phenotypic evolution. Next-generation sequencing precisely resolved the diagnostic dilemma of gynecologic SMMNs by delineating an ovarian origin and a complex evolutionary pattern, thereby proving critical for guiding personalized treatment and screening strategies, particularly in hereditary cancer syndromes.